Science 37®
TECHNOLOGIES

The Clinical Trial **Operating System.**

Disclaimers and Other Important Information

This presentation (this "Presentation") is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination between Science 37, Inc. ("Science 37") and LifeSci Acquisition II Corp. ("LSAQ") and related transactions (the "Potential Business Combination") and for no other purpose. By reviewing or reading this Presentation, you will be deemed to have agreed to the obligations and restrictions set out below. Without the express prior written consent of LSAQ and Science 37, this Presentation and any information contained within it may not be (i) reproduced (in whole or in part), (ii) copied at any time, (iii) used for any purpose other than your evaluation of Science 37 and the Potential Business Combination or (iv) provided to any other person, except your employees and advisors with a need to know who are advised of the confidentiality of the information. This Presentation supersedes and replaces all previous oral or written communications between the parties hereto relating to the subject matter hereof.

This Presentation and any oral statements made in connection with this Presentation do not constitute an offer to sell, or a solicitation of an offer to buy, or a recommendation to purchase, any securities in any jurisdiction, or the solicitation of any proxy, vote, consent or approval in any jurisdiction in connection with the Potential Business Combination or any related transactions, nor shall there be any sale, issuance or transfer of any securities in any jurisdiction where, or to any person to whom, such offer, solicitation or sale may be unlawful under the laws of such jurisdiction. This Presentation does not constitute either advice or a recommendation regarding any securities. Any offer to sell securities will be made only pursuant to a definitive subscription agreement and will be made in reliance on an exemption from registration under the Securities Act of 1933, as amended, for offers and sales of securities that do not involve a public offering. LSAQ and Science 37 reserve the right to withdraw or amend for any reason any offering and to reject any subscription agreement for any reason. The communication of this Presentation is restricted by law; it is not intended for distribution to, or use by any person in, any jurisdiction where such distribution or use would be contrary to local law or regulation.

No representations or warranties, express or implied are given in, or in respect of, this Presentation. To the fullest extent permitted by law, in no circumstances will LSAQ, Science 37 or any of their respective subsidiaries, stockholders, affiliates, representatives, partners, directors, officers, employees, advisers or agents be responsible or liable for any direct, indirect or consequential loss or loss of profit arising from the use of this Presentation, its contents (including the internal economic models), its omissions, reliance on the information contained within it, or on opinions communicated in relation thereto or otherwise arising in connection therewith. Industry and market data used in this Presentation have been obtained from third-party industry publications and sources as well as from research reports prepared for other purposes. Neither LSAQ nor Science 37 has independently verified the data obtained from these sources and cannot assure you of the data's accuracy or completeness. This data is subject to change. Recipients of this Presentation are not to construe its contents, or any prior or subsequent communications from or with LSAQ, Science 37 or their respective representatives as investment, legal or tax advice. In addition, this Presentation does not purport to be all-inclusive or to contain all of the information that may be required to make a full analysis of Science 37 or the Potential Business Combination. Recipients of this Presentation should each make their own evaluation of Science 37 and the Potential Business Combination and of the relevance and adequacy of the information and should make such other investigations as they deem necessary.

Forward-Looking Statements

This Presentation contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction between Science 37 and LSAQ, including statements regarding the benefits of the transaction, the anticipated timing of the transaction, the services offered by Science 37 and the markets in which it operates, and Science 37's projected future results. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result" and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this Presentation, including but not limited to: (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of LSAQ's securities, (ii) the risk that the transaction may not be completed by LSAQ's business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by LSAQ, (iii) the failure to satisfy the conditions to the consummation of the transaction, including the adoption of the agreement and plan of merger by the stockholders of LSAQ and Science 37, the satisfaction of the minimum trust account amount following redemptions by LSAQ's public stockholders and the receipt of certain governmental and regulatory approvals, (iv) the lack of a third party valuation in determining whether or not to pursue the proposed transaction, (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the agreement and plan of merger, (vi) the effect of the announcement or pendency of the transaction on Science 37's business relationships, performance, and business generally, (vii) risks that the proposed transaction disrupts current plans of Science 37 and potential difficulties in Science 37 employee retention as a result of the proposed transaction, (viii) the outcome of any legal proceedings that may be instituted against Science 37 or against LSAQ related to the agreement and plan of merger or the proposed transaction, (ix) the ability to maintain the listing of LSAQ's securities on the Nasdaq Capital Market ("Nasdaq"), (x) the price of LSAQ's securities may be volatile due to a variety of factors, including changes in the competitive and highly regulated industries in which Science 37 plans to operate, variations in performance across competitors, changes in laws and regulations affecting Science 37's business and changes in the combined capital structure (xi) the ability to implement business plans, forecasts, and other expectations after the completion of the proposed transaction, and identify and realize additional opportunities, and (xii) the potential adverse effects of the ongoing global COVID-19 pandemic. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of LSAQ's Registration Statement on Form S-1, the registration statement on Form S-4 and proxy statement/consent solicitation statement/prospectus described below and other documents filed by LSAQ from time to time with the U.S. Securities and Exchange Commission (the "SEC"). These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Science 37 and LSAQ assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither Science 37 nor LSAQ gives any assurance that either Science 37 or LSAQ will achieve its expectations.

Disclaimers and Other Important Information (continued)

Use of Projections
This Presentation contains projected financial information with respect to Science 37. Such projected financial information constitutes forward-looking information and is for illustrative purposes only and should not be relied upon as necessarily being indicative of future results. The assumptions and estimates underlying such financial forecast information are inherently uncertain and are subject to a wide variety of significant business, economic, competitive and other risks and uncertainties. See "Forward-Looking Statements" above. Actual results may differ materially from the results contemplated by the financial forecast information contained in this Presentation, and the inclusion of such information in this Presentation should not be regarded as a representation by any person that the results reflected in such forecasts will be achieved.

Financial Information; Non-GAAP Financial Terms
The financial information and data contained this Presentation is unaudited and does not conform to Regulation S-X promulgated by the SEC. Accordingly, such information and data may not be included in, may be adjusted in, or may be presented differently in, any proxy statement/consent solicitation statement/prospectus or registration statement or other report or document to be filed or furnished by LSAQ with the SEC.

Furthermore, some of the projected financial information and data contained in this Presentation, such as Adjusted EBITDA (and related measures), has not been prepared in accordance with United States generally accepted accounting principles ("GAAP"). Science 37 and LSAQ believe these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to Science 37's financial condition and results of operations. Science 37's management uses these non-GAAP measures for trend analyses and for budgeting and planning purposes. Science 37 and LSAQ believe that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating projected operating results and trends in and in comparing Science 37's financial measures with other similar companies, many of which present similar non-GAAP financial measures to investors. Management of Science 37 does not consider these non-GAAP measures in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in Science 37's financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-GAAP financial measures. You should review Science 37's audited financial statements, which will be presented in LSAQ's proxy statement/consent solicitation statement/prospectus to be filed with the SEC, and not rely on any single financial measure to evaluate Science 37's business. A reconciliation of non-GAAP financial measures in this Presentation to the most directly comparable GAAP financial measures is not included, because, without unreasonable effort, Science 37 is unable to predict with reasonable certainty the amount or timing of non-GAAP adjustments that are used to calculate these Non-GAAP financial measures.

Trademarks
This Presentation contains trademarks, service marks, trade names, and copyrights of Science 37, LSAQ and other companies, which are the property of their respective owners.

Additional Information and Where to Find It
This document relates to a proposed transaction between Science 37 and LSAQ. This document does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. LSAQ intends to file a registration statement on Form S-4 that will include a proxy statement of LSAQ, a consent solicitation statement of Science 37 and a prospectus of LSAQ. The proxy statement/consent solicitation statement/prospectus will be sent to all LSAQ and Science 37 stockholders. LSAQ also will file other documents regarding the proposed transaction with the SEC. Before making any voting decision, investors and security holders of LSAQ and Science 37 are urged to read the registration statement, the proxy statement/consent solicitation statement/prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction.

Investors and security holders will be able to obtain free copies of the proxy statement/consent solicitation statement/prospectus and all other relevant documents filed or that will be filed with the SEC by LSAQ through the website maintained by the SEC at www.sec.gov. In addition, the documents filed by LSAQ may be obtained free of charge from LSAQ's website at www.lifesciacquisition.com/spac-2/ or by written request to LSAQ at LifeSci Acquisition II Corp., 250 West 55th Street, Suite 34, New York, NY 10019.

Participants in Solicitation
LSAQ and Science 37 and their respective directors and officers may be deemed to be participants in the solicitation of proxies from LSAQ's stockholders in connection with the proposed transaction. Information about LSAQ's directors and executive officers and their ownership of LSAQ's securities is set forth in LSAQ's filings with the SEC, including LSAQ's Registration Statement on Form S-1, which was filed with the SEC on October 14, 2020. To the extent that holdings of LSAQ's securities have changed since the amounts printed in LSAQ's Registration Statement on Form S-1, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of those persons and other persons who may be deemed participants in the proposed transaction may be obtained by reading the proxy statement/prospectus regarding the proposed transaction when it becomes available. You may obtain free copies of these documents as described in the preceding paragraph.

Risk Factors

Risks related to our limited operating history and early stage of growth

1. We have a limited operating history on which to assess the prospects for our business and we have incurred losses since inception. We anticipate that we will continue to incur significant losses for at least the next several years.
2. We have incurred significant losses since inception. As such, you cannot rely upon our historical operating performance to make an investment or voting decision regarding the company.
3. We have experienced rapid growth and expect to invest in growth for the foreseeable future. If we fail to manage growth effectively, our business, operating results and financial condition would be adversely affected.
4. We may need to raise additional funding to expand the commercialization of our products and services and to expand our research and development efforts. This additional financing may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product commercialization or development efforts or other operations.
5. A failure to identify and successfully close and integrate strategic acquisition targets could adversely impact our ongoing business and financial results.
6. Unfavorable general economic conditions could negatively affect our business, results of operations and financial condition.
7. Our actual operating results may differ significantly from guidance provided by our management.

Risks related to our business and operations

1. Our forecasts and projections are based upon assumptions, analyses and internal estimates developed by our management. If these assumptions, analyses or estimates prove to be incorrect or inaccurate, our actual operating results may differ materially from those forecasted or projected.
2. The potential loss, delay, or non-renewal of our contracts or any delay in our clients' clinical trials or non-payment by our clients for services that we have performed, could negatively affect our business, results of operations and financial results.
3. Our backlog may not convert to revenue at the historical conversion rate.
4. If we are unable to successfully develop and market new services or enter new markets, our growth, results of operations or financial condition could be adversely affected.
5. Our relationships with existing or potential clients who are in competition with each other may adversely impact the degree to which other clients or potential clients use our services, which may adversely affect our results of operations.
6. If we are unable to attract suitable investigators and patients for our clinical trials, our clinical development business may suffer.
7. We rely on third parties for important products and services.
8. If we lose the services of key personnel or are unable to recruit and retain experienced personnel, our business could be adversely affected.
9. Failure to meet productivity objectives under our internal business transformation initiatives could adversely impact our competitiveness and harm our operating results.
10. Our insurance may not cover all of our indemnification obligations and other liabilities associated with our operations.
11. We derive a significant percentage of our revenues from a concentrated group of clients and the loss of one or more major clients could materially and adversely affect our business, results of operations or financial condition.
12. Current and future litigation against us, which may arise in the ordinary course of our business, could be costly and time consuming to defend.
13. We expect to incur increased costs and obligations as a result of being a public company.
14. While we to date have not made material acquisitions, should we pursue acquisitions in the future, we would be subject to risks associated with acquisitions.

Risk Factors (continued)

Risks related to the general economic and financial market conditions and the industries in which we operate

1. The effects of the COVID-19 pandemic could adversely affect our business, results of operations, and financial condition.
2. We depend entirely on the clinical trial market, and a downturn in this market could cause our revenues to decrease.
3. Consolidation among our clients could cause us to lose clients, decrease the market for our products and result in a reduction of our revenues.
4. Our estimate of the market size for our services may prove to be inaccurate, and even if the market size is accurate, we cannot assure you that our business will serve a significant portion of the market.

Risks related to technology and intellectual property

1. Our business depends on the continued effectiveness and availability of our information systems, including the information systems we use to provide our services to our clients, and failures of these systems may materially limit our operations.
2. A failure or breach of our IT systems or technology could result in sensitive client information being compromised or otherwise significantly disrupt our business operations, which would negatively materially affect our reputation and/or results of operations.
3. Computer malware, viruses, ransomware, hacking, phishing attacks and other network disruptions could result in security and privacy breaches and interruption in service, which would harm our business.
4. Our services are subject to evolving industry standards and rapid technological changes. If we do not keep pace with rapid technological changes, our services may become less competitive or obsolete, which could have a material adverse effect on our business, results of operations and financial condition.
5. We rely on third parties to provide certain data and other information to us. Our suppliers or providers might increase our cost to obtain, restrict our use of, or refuse to license data, which could lead to our inability to access certain data or provide certain services and, as a result, materially and adversely affect our operating results and financial condition.
6. We rely on third parties for important products, services and licenses to certain technology and intellectual property rights and we might not be able to continue to obtain such products, services and licenses.
7. We have only a limited ability to protect our intellectual property rights, both domestically and internationally, and these rights are important to our success.
8. Our cloud-based solutions and services utilize open source software, and any failure to comply with the terms of one or more of these open source licenses could adversely affect our business.

Risks related to political, legal and regulatory environment

1. We may face political, legal and compliance, operational, regulatory, economic and other risks associated with the international expansion of our operations that we do not currently face or that are more significant than in our domestic operations.
2. Due to the global nature of our business, we may be exposed to liabilities under anti-corruption laws, including the United States Foreign Corrupt Practices Act, the United Kingdom Bribery Act and various international anti-corruption laws, and any allegation or determination that we violated these laws could have a material adverse effect on our business.
3. Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.
4. If we fail to comply with certain healthcare laws, including fraud and abuse laws, we could face substantial penalties and our business, results of operations, financial condition, and prospects could be adversely affected.
5. Extensive governmental regulation of the clinical trial process and our products and services could require significant compliance costs and have a material adverse effect on the demand for our solutions.
6. Data protection laws and regulations may limit the use of our platform and give rise to operational interruption, liabilities, and reputational harm, which could have a materially adverse impact on our business.
7. The enactment of legislation implementing changes in the U.S. taxation of international business activities, the adoption of other tax reform policies or changes in tax legislation or policies in jurisdictions outside of the United States could materially impact our results of operations and financial condition.

Risk Factors (continued)

Risk related to our common stock

1. Future sales of our stock in the public market could cause the market price of our stock to decrease significantly.
2. If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, our stockholders could lose confidence in our financial and other public reporting, which would harm its business and the trading price of our common stock.
3. Since we have no current plans to pay regular cash dividends on our common stock, stockholders may not receive any return on investment unless they sell their common stock for a price greater than that which they paid for it.
4. If securities analysts or industry analysts do not publish reports about our business or if they downgrade our stock or our sector, our stock price and trading volumes could decline.
5. Delaware law and provisions in our certificate of incorporation and bylaws could make a takeover proposal more difficult.
6. Our bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings and the federal district courts as the sole and exclusive forum for other types of actions and proceedings, in each case, that may be initiated by our stockholders, which could limit our stockholders' ability to obtain what such stockholders believe to be a favorable judicial forum for disputes with the company or our directors, officers or other employees.

Today's Presenters

David Coman

CEO

Science 37

Mike Zaranek

CFO

Science 37

Dave Dobkin

CFO

Life Sci Acquisition II

Transaction Overview.

Science 37 has agreed to key terms of a potential business combination with LifeSci Acquisition II Corp. (LifeSci)

Transaction Structure:	$80.1M cash in trust[(a)]; $200.0M PIPE proceeds Selling shareholders of the company to receive newly issued shares of SPAC common stock at $10.00 per share and an additional 12.5 million shares subject to a price-based earnout[(b)]
Use of Proceeds:	The company intends to use the net proceeds from the transaction for geographic expansion, to expand its tech platform to further service pharma and to pursue M&A opportunities
Valuation:	$1,300 pro forma equity value; $1,050 pro forma fully-diluted TEV with no debt outstanding at closing
Timeline:	Proposed transaction announcement date during the week of May 3rd

(a) Assumes no redemption from LifeSci's existing public shareholders.

(b) 5 million earnout shares at $15.00 and 7.5 million earnout shares at $20.00 (for 20 trading days of any consecutive 30 trading day period following closing)

Transaction Detail.

Sources, Uses. and Pro Forma Cap Table

SOURCES

($M)	
Common Stock Issued to S37	$1,000
Cash Held in Trust[a]	80
PIPE	200
Total Sources	**$1,280**

USES

($M)	
Common Stock Issued	$1,000
Payment of Transaction Expenses	30
Cash to Balance Sheet	250
Total Uses	**$1,280**

PRO FORMA VALUATION

($M, %)	PF Shares	Ownership
LSAQ Sponsor Shares	2.0	1.5%
Public Shareholders	8.0	6.2%
S37 Roll-Over	100.0	76.9%
PIPE	20.0	15.4%
Pro Forma Shares Outstanding[b]	**130.0**	**100.0%**
Share Price		$10.00
Pro Forma Shares Outstanding		130.0
Total Equity Value ($10 per share)		**$1,300.1**
Plus: Debt		0
Less: Cash		(250)
Pro Forma Fully-Diluted TEV		**$1,050.0**
2023E Revenue		$182.50
EV / 2023E Revenue		**5.8x**

ILLUSTRATIVE PRO FORMA OWNERSHIP[b]



Note: deal is on a cash free, debt free basis.

(a) Assumes no redemption from LifeSci's existing public shareholders.

(b) Share count excludes i) 3.146M private placement warrants (strike price of $11.50) that are expected to be converted into share of common stock at the closing and ii) 12.5M of seller earnout shares (5M shares vesting at $15.00 / share and 7.5M vesting at $20.00 / share).

Highly Experienced in Technology and Science.

David Coman
Chief Executive Officer

Mike Zaranek
Chief Financial Officer

Steven Geffon
Chief Commercial Officer

Darcy Forman
Chief Delivery Officer



Jim Young
Chief HR Officer

Jonathan Cotliar
Chief Medical Officer

Chris Ceppi
Chief Product Officer

Drew Bustos
Chief Strategy and Marketing Officer

Laura Podolsky
General Counsel

Anita Modi
VP Business Transformation

QUINTILES ERT IQVIA EY medrio ERT FIRMA CLINICAL RESEARCH Clinipace CLINICAL RESEARCH WebMD aptuit

Harbor-UCLA MEDICAL CENTER Mucker Capital PING IQVIA ERT THEODORA ORINGHER athenahealth

Investing in our **Foundation of Success.**

Rob Faulkner

Redmile Group

Chairman

John Hubbard

SIGNANT HEALTH

Pfizer | BIOCLINICA RESEARCH

Independent

Adam Goulburn

LUX+

Bhooshi Desilva

PPD

Neil Tiwari

NOVARTIS

Scott Jordan

GLYNN CAPITAL MANAGEMENT

Observer

Investors:

LUX+

GLYNN CAPITAL™

PPD INVESTMENTS, LLC

AMGEN

NOVARTIS

LIFESCI VENTURE PARTNERS

Redmile Group

SANOFI VENTURES

G/

MUBADALA

Science 37 Investment Highlights.

Disrupting the $60b Clinical Trial Industry

- Up to 15x faster than traditional clinical trials
- Up to 28x greater patient/participant retention
- Up to 3x more diverse participants

Category-Defining Clinical Trial Operating System

- Unifying technology platform to enable workflow, evidence generation and data harmonization
- On-demand telemedicine investigators and *gig-economy* nursing for home visits
- Integrations into networks (EHR and EDC) and connected devices to expedite trial operations

Strong Financial Performance

- $444M net bookings in 2025 expected to increase from $119M in 2021
- $362M revenue in 2025 expected to increase from $52M in 2021
- Gross profit margin expected to increase to 55% in 2025



Significant Growth Opportunities Ahead

- Model expansion: commercial, geographic, technology
- Expanded offerings: rapidly growing adjacencies
- Potential M&A opportunities

Clinical Trial Model is Ripe for Disruption.

Traditional Site-Centric Model is Not Working…

Clinical Trial model has not changed in >90 years

- Multiple legacy technologies with technical debt
- Poorly integrated systems lead to redundant resources and duplicate work
- Redundant processes to fully leverage new technologies and workflow

Traditional Clinical Trials

1920s 2010s

Sponsor

Site

Coordinator
Investigator
Nurse

Contract Research Associates

Patients



Declining Performance

~ 80%[1]
TRIALS EXPERIENCE DELAYS

~ 20%[2]
AVG. PATIENT DROPOUT RATE

~ 14%[3]
MINORITIES REPRESENTED

7-13[4]
YEARS TO LAUNCH A DRUG

1. Source: Article from Drug Development & Drug delivery https://drug-dev.com/cost-of-disrupted-clinical-research-due-to-covid-19-equates-to-10-billion-potential-study-delays
2. Source: Tufts Center for the Study of Drug Development – Impact Report – Volume 22 Number 1 – January/February 2020: https://static1.squarespace.com/static/5a9eb0c8e2ccd1158288d8dc/t/5e303c3dd4520c015cb8a4b1/1580219453985/JanFeb2020_CropSummary.JPG
3. Source: Article from Nature - When will clinical trials finally reflect diversity? – 09 May 2018: https://www.nature.com/articles/d41586-018-05049-5
4. Source: Tufts Center for the Study of Drug Development – Impact Report – Volume 20 Number 3 – May/June 2018 as it relates to non-orphan drugs: https://static1.squarespace.com/static/5a9eb0c8e2ccd1158288d8dc/t/5af455f9352f53cd2156399e/1525962233431/summary_mayjune18.pdf%20

Science 37 Pioneered Decentralized Clinical Trials.

Patient Centric Model Generates Better Outcomes

Patient Centric Model

- Unified platform
- Proven processes
- Differentiated Services

Decentralized Clinical Trials

Science 37 Pioneers Virtual Trials in 2014

7 Years of insights in DCT

We've conducted more fully virtual trials.

95+
decentralized clinical trials (DCTs)

366,000+
engaged patients



Science 37 Technologies Outcomes

Enroll Patients Faster
Up to **15x** faster than sites in same study

Retain Patients Longer
Up to **28%** longer than industry average

Represent the Real Population
Up to **3x** Higher enrollment from diverse communities

Pharma Gain in revenue
Potential of **>$54M** 3 months average trial acceleration

Source: Science 37 Internal case study, reports, and estimates

Our Vision

To be the category-defining Operating System that powers every clinical trial.

Full-Stack, E-2-E Technology & Network Enables Trial Orchestration.

Patient Communities

- Social media and association networks
- Provider, pharmacy and payer networks
- **FASTER PATIENT RECRUITMENT**

Telemedicine Investigators

- On-demand, experience rated
- All therapeutic areas; any geography
- **ACCESS TO ANY PATIENT, ANYWHERE**

Mobile Nurses

- On-demand, gig-economy motivated
- Managed via one set of SOPs
- **PATIENT-CENTRIC FOCUSED EXPERIENCE**

Remote Coordinators

- Highly scalable
- Measurable utilization rates
- **REPEATABLE PROCESSES**

Connected Devices

- Flexibility to integrate with virtually any device
- New clinical data (cardiac, activity, sleep, lung function, etc)
- **ROBUST, REAL-TIME EVIDENCE GENERATION**



Full-Stack, E-2-E Technology Platform.

DCT Operating System

Patient Communities

Remote Coordinators

Telemedicine Investigators

Mobile Nurses

Connected Devices

Full-Stack, E-2-E Technology Platform.



Patient Communities

Remote Coordinators

Telemedicine Investigators

Mobile Nurses

Connected Devices

Full-Stack, E-2-E Technology Platform.



Creating Optimal **Trial Orchestration.**



Creating Optimal **Trial Orchestration.**





Creating Optimal **Trial Orchestration.**





Creating Optimal **Trial Orchestration.**



Creating Optimal **Trial Orchestration.**



DCT Configurations to Enable Any Study.

	Science 37 Platform	Trial Orchestration	Sole Provider
Full DCT	✓	✓	✓
Metasite ™	✓	✓	
Technology	✓		

Technology Configurations	Patient Engagement	Remote eConsent	eSource (eCOA, eCRF)	Telemedicine	3rd-Party Integration
Network Configurations	Patient Recruitment	Coordinator Network	Mobile Nurse Network	Investigator Network	Connected Devices
Study Configurations	Early Phase	Pivotal Studies	Long-Term Follow-up	Real-World Evidence	Any Indications

Science 37 is a Pioneer & Leader in DCT.

Large Pharma Customers

AMGEN · Boehringer Ingelheim · gsk · Genentech · Roche · janssen (Pharmaceutical Companies of Johnson & Johnson) · NOVARTIS · SANOFI

Mid-Size Pharma Customers

Incyte · REGENERON · ucb

Biotech Customers

Adrenas (a bridgebio company) · adagio · ARENA PHARMACEUTICALS · ascendis pharma · freenome · HARMONY BIOSCIENCES · moderna · allo vir · VectivBio · Voyager THERAPEUTICS · advicenne · QOL Medical

Academic/Gov't Customers

BILL & MELINDA GATES MEDICAL RESEARCH INSTITUTE · NIH National Institutes of Health *Turning Discovery Into Health* · FDA U.S. FOOD & DRUG ADMINISTRATION · Duke Clinical Research Institute · USC Dermatology

Press & Awards

BioSpace · BUSINESS INSIDER · Digital Health 150 CBINSIGHTS · FIERCE Biotech · Forbes · TechCrunch · THE WALL STREET JOURNAL. · FORTUNE

Partnerships

ADVARRA · AiCure · DATAVANT · FOUNDATION MEDICINE · ERT · Hillrom · medgate · PPD · SIGNANT HEALTH · Syneos Health · Xperiome

Customer Success Stories.

Decentralization on Massive Scale.

Oncology Diagnostic Pivotal Trial

Situation

- **Rescued top-CRO traditional brick & mortar study with enrollment challenges**

Approach

- Patient enrollment
- Phlebotomist visit
- Follow-up after colonoscopy

Outcomes

5,380+

enrolled in just half of the total recruitment period

2,000+

Enrolled in a month

Faster Start-up and Greater Continuity of Care.

Breast Cancer Study

Situation

- **Needed a means to continue intravenous treatments for cancer study**

Approach

- Enrolled at site
- Telemedicine visit
- Chemotherapy delivered in-home by mobile nurse

Outcomes

4x

faster study start-up

"All clinical trials are special but this one… is above and beyond anything I have seen in my oncology career."

Executive Group Medical Director
Top 10 Pharma Company

Why Science 37 Wins[1].

- Tech is not in our competitors' DNA
- DCT model requires different SOPs
- DCT would cannibalize competitors' core business



Science 37 TECHNOLOGIES

The Clinical Trial Operating System

- Little to minimal ability to orchestrate
- User Experience (UX) not informed by their own users

1. Science 37 management team assessment based on competitor public announcements.

Why Science 37 Wins[1] in the Future.



1. Science 37 management team assessment based on competitor public announcements.

Science 37 Defines the Standard Clinical Trial OS.

Empowers Clinical Trials and Optimizes the Experience & Outcomes for Participants

Traditional, site-based trial + Decentralized trial (DCT)



Future Clinical Trials



To win in this new era, leaders will need the following:

- Ability to activate any Provider and any Patient – regardless of premises
- A network of traditional providers, telemedicine providers, mobile nurses and remote coordinators
- A flexible operating system to seamlessly navigate between on-site and off-site

Large Market Opportunity.

2021 Total Available Market (TAM) ~

$195 Billion R&D Spend





1. Pre-COVID forecast. Source: EvaluatePharma; BCG Analysis
2. Serviceable Available Market: Management estimates as of April 2021

Science 37 Growth Drivers.

01 Core

- SaaS and aPaaS
- Patient Platform (Recruitment, Enrollment, & Engagement)
- Globalization of Metasite
- Connected Devices at Scale
- Expanded Commercial Presence

02 Expand

- CRO
- eCOA
- RWE
- Clinical Care
- Diversity



03 Extend

- Provider Tech Enablement
- Provider Network Sources
- Performance & Risk Mgmt.

Disrupting a $60b[1] Market

Constructing the category-defining Clinical Trial Operating System

1. Serviceable Available Market: Management estimates as of April 2021

Top-Line Growth Acceleration.





*Q1-2021 Preliminary Bookings

Representative Bookings in Past 12 Months.

	Value	Indication	Phase	First Patient	Contract
Biotech	$4.1M	Infectious Disease	III	Apr 2021	18 Months
Top 5 pharma	$5.1M	Respiratory	III	May 2021	39 Months
Top 5 Pharma	$2.2M	Neurology	II	Apr 2021	9 Months
Biotech	$1.4M	Gastrointestinal	II	Jan 2021	24 Months
Biotech	$1.1M	Huntington's	II	Apr 2021	38 Months
Government	$22.6M	COVID	III	Apr 2021	36 Months
Biotech	$18.5M	Oncology	III	Jul 2020	12 Months
Top 5 pharma	$6.3M	Nephrology	III	May 2021	21 Months
Biotech	$2.7M	Nephrology	III	May 2021	8 Months
Biotech	$1.4M	Adrenal Hyperplasia	II	Mar 2021	12 Months
Biotech	$1.5M	CSID	IV	Jul 2021	19 Months
Top 5 pharma	$4.8M	Oncology	II	Nov 2020	36 Months
Biotech	$3.8M	FNAD	II	Jul 2021	8 Months
Biotech	$1.5M	CSID	IV	Jul 2021	19 Months
Biotech	$0.8M	Respiratory	IV	May 2021	8 Months

Tech+

Metasite

Full DCT

Global

Top-Line Acceleration.

Average Contract Value[2]



Net New Logos

Net Promoter Score[1] (NPS):

Science 37 NPS
40

Net Bookings thru 2025



1. Source: Science 37 Net Promoter Score Survey – Q4 2020 based on a limited number of survey responses
2. Based on Request for Proposals (RFPs) sent

Income Statement.

Significant Revenue Scaling



Gross Margin[3] Expansion



1. 2020 Figures are unaudited
2. As of April 12, 2021
3. Gross Margin excludes stock-based comp

Income Statement.

In 000's **Revenue**	**2019 Actuals**	**2020 Actuals**	**2021 Forecast**	**2022 Forecast**	**2023 Forecast**	**2024 Forecast**	**2025 Forecast**
Total Revenues	**$14,081**	**$23,704**	**$52,130**	**$102,253**	**$182,497**	**$261,319**	**$362,420**
Y-o-Y Growth	*N/A*	*68%*	*120%*	*96%*	*78%*	*43%*	*39%*
Cost of Revenues	7,852	22,597	35,658	55,271	91,208	120,602	164,690
Gross Profit	**$6,229**	**$1,107**	**$16,472**	**$46,982**	**$91,289**	**$140,718**	**$197,730**
Gross Margin %	*44%*	*5%*	*32%*	*46%*	*50%*	*54%*	*55%*
General and Adminstrative (ex. Dep/Amort & Stock-based Comp)	21,620	28,157	65,053	93,906	106,688	125,768	143,031
Adjusted EBITDA	**($15,391)**	**($27,050)**	**($48,580)**	**($46,924)**	**($15,399)**	**$14,949**	**$54,699**
Adj. EBITDA Margin %	*-109%*	*-114%*	*-93%*	*-46%*	*-8%*	*6%*	*15%*

Adjusted EBITDA is defined as net income, adjusted for: income taxes, depreciation and amortization, interest expense (net), stock-based compensation, other expense/(income), net, restructuring and related charges, and costs associated with this contemplated transaction.

Comparable Company Benchmarking.

Revenue CAGR 2021-2023



Enterprise Value / 2023E Revenue



Source: Company internal data, public filings, and CapitalIQ as of 5/6/21.

Selected Comparable Companies.

	EV/Revenue 2023E[(a)]	Revenue CAGR 2021-2023E[(a)]
Disruptive Healthcare Technology Platforms	9.1x	36%
Drug Discovery Enablement	15.4x	20%
Vertical Software	12.6x	16%
Science 37	5.8x	87%

(a) Figures presented are the mean for each category. Source: Company internal data, public filings, and CapitalIQ as of 5/6/21.

Science 37 Investment Highlights.

Disrupting the $60b Clinical Trial Industry

- Up to 15x faster than traditional clinical trials
- Up to 28x greater patient/participant retention
- Up to 3x more diverse participants

Category-Defining Clinical Trial Operating System

- Unifying technology platform to enable workflow, evidence generation and data harmonization
- On-demand telemedicine investigators and *gig-economy* nursing for home visits
- Integrations into networks (EHR and EDC) and connected devices to expedite trial operations

Strong Financial Performance

- $444M net bookings in 2025 expected to increase from $119M in 2021
- $362M revenue in 2025 expected to increase from $52M in 2021
- Gross profit margin expected to increase to 55% in 2025



Significant Growth Opportunities Ahead

- Model expansion: commercial, geographic, technology
- Expanded offerings: rapidly growing adjacencies
- Potential M&A opportunities